Kite Pharma

Kite Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. It has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. 
The engineered T cells are designed to recognize and destroy cancer cells. Its engineered autologous cell therapy (eACT) technology allows Kite to harness the power of a patient’s own immune system to effectively target and kill cancer cells. This process results in an expanded number of tumor-specific T cells that circulate throughout the body to systemically target and kill cancer cells, including those that have metastasized.

Company Growth (employees)
Type
Public
HQ
Santa Monica, US
Founded
2009
Size (employees)
447 (est)
Kite Pharma was founded in 2009 and is headquartered in Santa Monica, US

Kite Pharma Office Locations

Kite Pharma has offices in Santa Monica, El Segundo, Seattle, New York and in 31 other locations
Santa Monica, US (HQ)
2225 Colorado Ave
Amsterdam, NL
408 Science Park
Amsterdam, NL
Science Park 408
Show all (36)

Kite Pharma Data and Metrics

Kite Pharma Financial Metrics

Kite Pharma's revenue was reported to be $22.2 m in FY, 2016 which is a 28% increase from the previous period.
USD

Revenue (FY, 2016)

22.2 m

Revenue growth (FY, 2015 - FY, 2016), %

28%

Net income (FY, 2016)

(267.1 m)

EBIT (FY, 2016)

(273.2 m)

Market capitalization (21-Jul-2017)

5.7 b

Cash (31-Dec-2016)

114.6 m
Kite Pharma's current market capitalization is $5.7 b.
USDFY, 2015FY, 2016

Revenue

17.3 m22.2 m

Revenue growth, %

28%

R&D expense

76.4 m197.9 m

General and administrative expense

44.2 m97.4 m

Operating expense total

120.6 m295.4 m

EBIT

(103.3 m)(273.2 m)

EBIT margin, %

(599%)(1232%)

Interest expense

(658 k)(13 k)

Interest income

1.8 m3.6 m

Pre tax profit

(270 m)

Net Income

(101.7 m)(267.1 m)
USDFY, 2014FY, 2015FY, 2016

Cash

392.8 m114.6 m

Inventories

286 k16.4 m13 m

Current Assets

631.1 m427.4 m

PP&E

30.1 m44.4 m

Goodwill

25.4 m24.5 m

Total Assets

708 m524.3 m

Accounts Payable

8 m10.7 m

Current Liabilities

36.2 m55.1 m

Total Liabilities

96.3 m

Additional Paid-in Capital

775.6 m855.6 m

Retained Earnings

(159.7 m)(426.7 m)

Total Equity

615.8 m428 m

Financial Leverage

1.1 x1.2 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(101.7 m)(267.1 m)

Depreciation and Amortization

4.6 m10.6 m

Inventories

1.3 m(14.8 m)3.3 m

Accounts Payable

2.3 m4.5 m2.3 m

Cash From Operating Activities

(16.1 m)(168.9 m)

Purchases of PP&E

(26.6 m)(20.1 m)

Cash From Investing Activities

(108.1 m)(112.9 m)

Cash From Financing Activities

307.7 m3.7 m

Interest Paid

2 k13 k
Y, 2016

Financial Leverage

1.2 x

Kite Pharma Market Value History

Kite Pharma Job Categories

Kite Pharma Online and Social Media Presence

Kite Pharma News and Updates

Kite Pharma Company Life and Culture

You may also be interested in